Guangxing Yue1, Jingwen Tang1, Lihan Zhang1, Hong Niu1, Huahua Li1, Suxia Luo2. 1. Department of Integrated Chinese and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. 2. Department of Medicine Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Abstract
BACKGROUND: As an immune checkpoint that suppresses antitumor immunity, CD276 is a potential therapeutic target for cancer immunotherapy. However, the role of CD276 in esophageal squamous cell carcinoma (ESCC) has not been thoroughly examined. A greater understanding of the regulatory mechanism of CD276 may improve the clinical response and efficacy of cancer immunotherapy. METHODS: The expression of CD276 was measured by qRT-PCR, IHC and flow cytometry analysis. T cell infiltration in ESCC was measured by qRT-PCR and immunofluorescence analysis. The regulation function of CD276 in glucose metabolism was examined by metabolism assays, western blotting and small molecule inhibitors. Transfection was used for gene editing. The oncogenic function of CD276 was examined in vivo by CAR-T cell therapy model. RESULTS: Based on our findings, CD276 regulated the expression of the PKM2 gene in ESCC. Overexpression of CD276 induced the phosphorylation of PKM2 by the STAT3 signalling pathway to promote glucose metabolism in tumors. The accumulation of lactic acid in the tumor microenvironment has been reported to regulate the immune cells, particularly CD8+ T cells. We further analyzed the effect of CD276 on the function of T cells. Chimeric antigen receptor T cells (CAR-T) targeting human epidermal growth factor receptor 2 (HER2) were used as effector cells to detect the effect of CD276 on immunotherapy. The therapeutic effects of CAR-T cells were markedly limited by CD276 overexpression. CONCLUSIONS: Our results are the first to show that tumor-derived CD276 supports disease progression. Overexpression of CD276 promoted glucose metabolism in tumor and inhibited the function of CD8+ T cells. Therefore, strategies targeting CD276 might improve the response to cancer immunotherapy of ESCC patients. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: As an immune checkpoint that suppresses antitumor immunity, CD276 is a potential therapeutic target for cancer immunotherapy. However, the role of CD276 in esophageal squamous cell carcinoma (ESCC) has not been thoroughly examined. A greater understanding of the regulatory mechanism of CD276 may improve the clinical response and efficacy of cancer immunotherapy. METHODS: The expression of CD276 was measured by qRT-PCR, IHC and flow cytometry analysis. T cell infiltration in ESCC was measured by qRT-PCR and immunofluorescence analysis. The regulation function of CD276 in glucose metabolism was examined by metabolism assays, western blotting and small molecule inhibitors. Transfection was used for gene editing. The oncogenic function of CD276 was examined in vivo by CAR-T cell therapy model. RESULTS: Based on our findings, CD276 regulated the expression of the PKM2 gene in ESCC. Overexpression of CD276 induced the phosphorylation of PKM2 by the STAT3 signalling pathway to promote glucose metabolism in tumors. The accumulation of lactic acid in the tumor microenvironment has been reported to regulate the immune cells, particularly CD8+ T cells. We further analyzed the effect of CD276 on the function of T cells. Chimeric antigen receptor T cells (CAR-T) targeting human epidermal growth factor receptor 2 (HER2) were used as effector cells to detect the effect of CD276 on immunotherapy. The therapeutic effects of CAR-T cells were markedly limited by CD276 overexpression. CONCLUSIONS: Our results are the first to show that tumor-derived CD276 supports disease progression. Overexpression of CD276 promoted glucose metabolism in tumor and inhibited the function of CD8+ T cells. Therefore, strategies targeting CD276 might improve the response to cancer immunotherapy of ESCC patients. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Almut Brand; Katrin Singer; Gudrun E Koehl; Marlene Kolitzus; Gabriele Schoenhammer; Annette Thiel; Carina Matos; Christina Bruss; Sebastian Klobuch; Katrin Peter; Michael Kastenberger; Christian Bogdan; Ulrike Schleicher; Andreas Mackensen; Evelyn Ullrich; Stefan Fichtner-Feigl; Rebecca Kesselring; Matthias Mack; Uwe Ritter; Maximilian Schmid; Christian Blank; Katja Dettmer; Peter J Oefner; Petra Hoffmann; Stefan Walenta; Edward K Geissler; Jacques Pouyssegur; Andreas Villunger; André Steven; Barbara Seliger; Stephan Schreml; Sebastian Haferkamp; Elisabeth Kohl; Sigrid Karrer; Mark Berneburg; Wolfgang Herr; Wolfgang Mueller-Klieser; Kathrin Renner; Marina Kreutz Journal: Cell Metab Date: 2016-09-15 Impact factor: 27.287
Authors: Ranjana K Kanchan; Naveenkumar Perumal; Pranita Atri; Ramakanth Chirravuri Venkata; Ishwor Thapa; David L Klinkebiel; Andrew M Donson; Deborah Perry; Michael Punsoni; Geoffrey A Talmon; Donald W Coulter; Daniel R Boue'; Matija Snuderl; Mohd W Nasser; Surinder K Batra; Rajeev Vibhakar; Sidharth Mahapatra Journal: Brain Pathol Date: 2020-03-30 Impact factor: 6.508
Authors: Zixing Liu; Wenling Zhang; Joshua B Phillips; Ritu Arora; Steven McClellan; Jiangfeng Li; Jin-Hwan Kim; Robert W Sobol; Ming Tan Journal: Oncogene Date: 2018-08-06 Impact factor: 9.867
Authors: Elske C Gootjes; Jaco Kraan; Tineke E Buffart; Lotte Bakkerus; Barbara M Zonderhuis; Cornelis Verhoef; Henk M W Verheul; And Stefan Sleijfer Journal: Cells Date: 2020-01-05 Impact factor: 6.600
Authors: Uday B Maachani; Umberto Tosi; David J Pisapia; Sushmita Mukherjee; Christopher S Marnell; Julia Voronina; Daniel Martinez; Mariarita Santi; Nadia Dahmane; Zhiping Zhou; Cynthia Hawkins; Mark M Souweidane Journal: Transl Oncol Date: 2019-12-27 Impact factor: 4.243